Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Peregrine Pharmaceuticals stock collapses

Continue reading below

Peregrine Pharmaceuticals Inc.’s stock collapsed after the cancer drug developer said the survival rates from its mid-stage lung cancer study reported this month were unreliable, due to a third-party error in conducting the study. A tenfold rise in the stock price over the summer was lost, and the news removed nearly half a billion dollars in market value,
Wallstcheatsheet.com reported.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week